thermo fisher scientific inc. - TMO

TMO

Close Chg Chg %
565.22 -22.82 -4.04%

Closed Market

542.40

-22.82 (4.04%)

Volume: 3.22M

Last Updated:

Feb 5, 2026, 3:59 PM EDT

Company Overview: thermo fisher scientific inc. - TMO

TMO Key Data

Open

$565.11

Day Range

541.34 - 566.83

52 Week Range

385.46 - 643.99

Market Cap

$212.36B

Shares Outstanding

375.71M

Public Float

374.83M

Beta

0.93

Rev. Per Employee

N/A

P/E Ratio

31.86

EPS

$17.76

Yield

30.43%

Dividend

$0.43

EX-DIVIDEND DATE

Dec 15, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

2.67M

 

TMO Performance

1 Week
 
-2.31%
 
1 Month
 
-8.67%
 
3 Months
 
-1.26%
 
1 Year
 
-1.09%
 
5 Years
 
14.75%
 

TMO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About thermo fisher scientific inc. - TMO

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

TMO At a Glance

Thermo Fisher Scientific, Inc.
168 Third Avenue
Waltham, Massachusetts 02451
Phone 1-781-622-1000 Revenue 44.56B
Industry Medical Specialties Net Income 6.74B
Sector Health Technology 2025 Sales Growth 3.911%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

TMO Valuation

P/E Current 31.861
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 32.663
Price to Sales Ratio 4.916
Price to Book Ratio N/A
Price to Cash Flow Ratio 28.01
Enterprise Value to EBITDA 22.815
Enterprise Value to Sales 5.576
Total Debt to Enterprise Value 0.159

TMO Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 5.006
Total Asset Turnover 0.429

TMO Liquidity

Current Ratio 1.89
Quick Ratio 1.533
Cash Ratio 0.665

TMO Profitability

Gross Margin 37.656
Operating Margin 18.20
Pretax Margin 16.402
Net Margin 15.12
Return on Assets 6.488
Return on Equity 13.082
Return on Total Capital 7.26
Return on Invested Capital 7.966

TMO Capital Structure

Total Debt to Total Equity 73.734
Total Debt to Total Capital 42.441
Total Debt to Total Assets 35.693
Long-Term Debt to Equity 67.12
Long-Term Debt to Total Capital 38.634
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Thermo Fisher Scientific Inc. - TMO

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
44.91B 42.86B 42.88B 44.56B
Sales Growth
+14.55% -4.58% +0.05% +3.91%
Cost of Goods Sold (COGS) incl D&A
25.90B 25.66B 25.15B 27.78B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.38B 3.41B 3.11B 2.78B
Depreciation
986.00M 1.07B 1.16B 1.05B
Amortization of Intangibles
2.40B 2.34B 1.95B 1.73B
COGS Growth
+32.32% -0.93% -2.00% +10.44%
Gross Income
19.01B 17.19B 17.73B 16.78B
Gross Income Growth
-3.17% -9.56% +3.11% -5.36%
Gross Profit Margin
+42.33% +40.12% +41.34% +37.66%
2022 2023 2024 2025 5-year trend
SG&A Expense
10.49B 9.75B 10.07B 8.67B
Research & Development
1.47B 1.34B 1.39B 1.40B
Other SG&A
9.02B 8.41B 8.68B 7.27B
SGA Growth
+12.56% -7.04% +3.26% -13.88%
Other Operating Expense
- - - -
-
Unusual Expense
131.00M 496.00M 73.00M 356.00M
EBIT after Unusual Expense
8.39B 6.95B 7.59B 7.75B
Non Operating Income/Expense
167.00M 839.00M 1.10B 975.00M
Non-Operating Interest Income
272.00M 879.00M 1.08B 993.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
726.00M 1.49B 1.65B 1.42B
Interest Expense Growth
+35.45% +105.37% +10.93% -14.21%
Gross Interest Expense
726.00M 1.49B 1.65B 1.42B
Interest Capitalized
- - - -
-
Pretax Income
7.83B 6.30B 7.04B 7.31B
Pretax Income Growth
-11.38% -19.62% +11.73% +3.85%
Pretax Margin
+17.44% +14.70% +16.41% +16.40%
Income Tax
703.00M 284.00M 657.00M 547.00M
Income Tax - Current - Domestic
- 1.07B 378.00M 691.00M
Income Tax - Current - Foreign
- 633.00M 1.21B 1.18B
Income Tax - Deferred - Domestic
- (683.00M) (653.00M) (1.14B)
Income Tax - Deferred - Foreign
- (314.00M) (647.00M) (72.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.96B 5.96B 6.34B 6.75B
Minority Interest Expense
10.00M (40.00M) 3.00M 17.00M
Net Income
6.95B 6.00B 6.33B 6.74B
Net Income Growth
-10.03% -13.74% +5.67% +6.35%
Net Margin Growth
+15.47% +13.99% +14.77% +15.12%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
6.95B 6.00B 6.33B 6.74B
Preferred Dividends
- - - -
-
Net Income Available to Common
6.95B 6.00B 6.33B 6.70B
EPS (Basic)
17.7296 15.5311 16.5838 17.7825
EPS (Basic) Growth
-9.57% -12.40% +6.78% +7.23%
Basic Shares Outstanding
392.00M 386.00M 382.00M 377.00M
EPS (Diluted)
17.6396 15.451 16.5405 17.74
EPS (Diluted) Growth
-9.35% -12.41% +7.05% +7.25%
Diluted Shares Outstanding
394.00M 388.00M 383.00M 378.00M
EBITDA
11.91B 10.85B 10.77B 10.89B
EBITDA Growth
-7.78% -8.85% -0.76% +1.10%
EBITDA Margin
+26.51% +25.32% +25.12% +24.44%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 666.90
Number of Ratings 28 Current Quarters Estimate 5.266
FY Report Date 03 / 2026 Current Year's Estimate 24.563
Last Quarter’s Earnings 6.57 Median PE on CY Estimate N/A
Year Ago Earnings 22.87 Next Fiscal Year Estimate 26.872
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 20 20 24 23
Mean Estimate 5.27 5.82 24.56 26.87
High Estimates 5.55 6.01 25.00 27.64
Low Estimate 5.02 5.65 24.30 26.37
Coefficient of Variance 2.11 1.68 0.56 1.21

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 19 16
OVERWEIGHT 4 4 5
HOLD 6 6 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Thermo Fisher Scientific Inc. - TMO

Date Name Shares Transaction Value
Jan 7, 2026 Scott M. Sperling Director 17,502 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 Karen S. Lynch Director 225 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 R. Alexandra Keith Director 1,204 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 29, 2025 Gianluca Pettiti Executive Vice President 22,367 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $479.98 per share 10,735,712.66
Apr 2, 2025 Ingrid Freire Director 2,401 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 2, 2025 Jennifer M. Johnson Director 398 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Michael A. Boxer SVP and General Counsel 10,816 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $532.52 per share 5,759,736.32
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 123,174 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $253.99 per share 31,284,964.26
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 115,174 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $524.22 per share 60,376,514.28
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 116,419 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $523.29 per share 60,920,898.51
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 119,024 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $518.62 per share 61,728,226.88
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 120,724 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $517.39 per share 62,461,390.36
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 122,574 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $515.59 per share 63,197,928.66
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 122,974 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $514 per share 63,208,636.00
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 115,274 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $523.01 per share 60,289,454.74
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 115,576 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $521.52 per share 60,275,195.52
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 116,979 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $517.87 per share 60,579,914.73
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 118,597 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $516.72 per share 61,281,441.84
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 120,395 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $515.89 per share 62,110,576.55
Mar 7, 2025 Marc N. Casper Chairman & CEO; Director 122,283 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $514.58 per share 62,924,386.14

Thermo Fisher Scientific Inc. in the News